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the cost to achieve full glycemic control (HbA1c  7%)
with each first-line strategy. Each monotherapy could be
succeeded by add-on treatments. The model included
costs of routine medical care/supplies, medication, ad-
verse events, and treatment failures. 
RESULTS: Using a deterministic approach (with Monte
Carlo results in parentheses), the 3-year cumulative costs
per patient were $4867 ($4971), $5196 ($5273), and
$5249 ($5311) for glipizide GITS, metformin, and acar-
bose first-line strategies, respectively. Main cost drivers
were drug prices. Mean 3-year cost savings for first-line
glipizide GITS were $301 over metformin, and $340 over
acarbose. Between 83% to 85% of all simulations showed
cost savings with glipizide GITS over the other agents. 
CONCLUSIONS: Our model suggests first-line monother-
apy with glipizide GITS should result in desirable short-
term economic benefits to MCOs. Because the model in-
corporates recommended glycemic goals and performed
well in sensitivity analyses, we believe it is applicable to a
variety of clinical practices and useful for economic assess-
ments of new therapies. Results of this model should be
verified prospectively in typical care settings.
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OBJECTIVE: The purpose of this study was to develop
and refine holistic health state descriptions of diabetic pe-
ripheral neuropathy (DPN) and its complications for a
new utility instrument. 
METHODS: Quality of life domains and health state de-
scriptions related to DPN were developed through a liter-
ature review, previous focus group materials, and expert
opinion. Potential corresponding photographs were iden-
tified by expert opinion. Sixteen veterans with DPN-
related complications were recruited to participate in fo-
cus group discussions of DPN and its impact on quality
of life. Demographic and SF-36 data were also collected.
Semi-structured discussion on the health state descrip-
tions and the quality of life domains were used to refine
and face validate the health state descriptions. A psycho-
metric analysis was performed on eight additional pa-
tients to identify the most appropriate photographs to ac-
company each health state description. 
RESULTS: The mean SF-36 Physical and Mental Com-
ponent Summary scales of the participants were 28.32
and 51.69, respectively. Four broad quality of life do-
mains: symptoms of DPN (numbness, tingling, sensation,
pain, temperature detection), physical function (mobil-
ity), social function (family, leisure activities, social life)
and mental/emotional function (affect, mood, cognition)
were identified. Qualitative exploration of these domains
in four focus group discussions affirmed that these were
the domains of importance to patients. Analysis of the
empiric data from the psychometric experiment unequiv-
ocally demonstrated the photographs to accompany the
health state descriptions. 
CONCLUSIONS: Eight health state descriptions with
photographs were refined and validated by patients.
These health state descriptions will be used with U-Titer,
a customizable utility elicitation software package, to de-
rive preference weights from an at-risk population in
Canada (N  60) and the United Kingdom (N  60).
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OBJECTIVES: The aims of this research were to 1) com-
pare onychomycosis infection rates in patients with and
without diabetes, and 2) determine the impact of onycho-
mycosis on the development of secondary infections in
the diabetic population. 
METHODS: Patients with onychomycosis or diabetes
were identified from the Clinical Care in America (CCIA)
Managed Care database. Those continually enrolled in a
1-year period between 1995–1996 were classified as hav-
ing onychomycosis with or without diabetes and rates of
secondary infection within the following 12 months were
analyzed adjusting for age and gender. Using the 1995
MEDSTAT database of diabetic claims, patients with a
claim for onychomycosis along with a random sample of
those without onychomycosis were identified in addition
to frequency of secondary infection. Logistic regression
was used to estimate the relative risk of developing gan-
grene or foot ulcer adjusting for age and uncomplicated
diabetic payments. 
RESULTS: In CCIA, onychomycosis was more prevalent in
diabetic patients (5.9%) relative to patients without diabe-
tes (0.8%). Likewise, the secondary infection rate among
diabetics with onychomycosis was higher relative to diabet-
ics without onychomycosis (15% and 6%, respectively).
Diabetic patients with onychomycosis in MEDSTAT had a
higher percent of gangrene and foot ulcer (12.2%) relative
to those without onychomycosis (3.8%) and had an ap-
proximate three-fold higher risk of developing gangrene or
foot ulcer. 
CONCLUSION: Results suggest that patients with dia-
betes may have higher rates of onychomycosis, which
negatively impact the development of secondary infec-
tions (gangrene and foot ulcer), relative to patients with-
out diabetes. The impact of onychomycosis on humanis-
tic and economic outcomes in the diabetic population is
the subject of current research, and should lend further
evidence to support appropriate therapy.
